ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Hepatocellular carcinoma"

  • 2021 American Transplant Congress

    Waitlist Outcomes for Exception Candidates Following the Implementation of MMaT/250 Score

    T. Ishaque1, J. G. Wang1, S. Karhadkar2, D. Segev1, A. B. Massie1

    1Johns Hopkins Medical Institutions, Baltimore, MD, 2Temple University, Philadelphia, PA

    *Purpose: Starting in May 2019, exception points were allocated based on DSA-level median-MELD-at-transplant (MMaT/DSA). In February 2020, the exception point system was further modified based…
  • 2020 American Transplant Congress

    Biomarkers AFP in Combination with AFP-l3 and DCP Predicts Tumor Progression in Treatment Native HCC Patients

    K. Nunez, T. Sandow, P. Thevenot, A. Cohen

    Ochsner Health System, New Orleans, LA

    *Purpose: Hepatocellular carcinoma (HCC) treatment with locoregional therapy (LRT) is standard treatment to downstage within Milan Criteria. In this study, we retrospectively analyzed early-stage HCC…
  • 2020 American Transplant Congress

    Bad Actors within Milan Criteria Undergoing OLT- Characterizing Their Pre-Transplant Tumor Behavior and Response to Locoregional Therapy

    A. Mathur, E. Baughan, A. Griesemer, M. Najjar, O. Perez, A. Qian, T. Kato, J. Emond

    Columbia University, New York, NY

    *Purpose: Orthotopic Liver Transplantation (OLT) remains a curative option for hepatocellular carcinoma (HCC). Disparity between the supply and demand for OLT necessitates the transplant of…
  • 2020 American Transplant Congress

    The Perioperative Coagulation Profile of Hepatocellular Carcinoma During Liver Transplantation Compared to Patients with Non-Malignant Disease: A Cause or Association for Decreased Blood Product Utilization During Liver Transplantation?

    H. B. Moore, E. Pomfret, J. Pomposelli, C. Walker, R. Choudhury, H. Yaffe, M. Wachs, T. Bak, K. Conzen, M. Adams, T. Pshak, T. L. Nydam

    University of Colorado, Aurora, CO

    *Purpose: Hepatobiliary malignancies have been associated with hyper-coagulability. However, the impact of hepatocellular carcinoma (HCC) on coagulation during liver transplantation remains less clear. We hypothesize…
  • 2020 American Transplant Congress

    Shorter Waiting Time Was Associated with Higher Risk of Recurrence of Hepatocellular Carcinoma in Liver Transplantation

    T. Kitajima1, S. Nagai1, D. Moonka2, S. Yeddula1, O. Rizzo1, M. Kavousi1, R. Salgia2, M. Rizzari1, K. Collins1, A. Yoshida1, M. S. Abouljoud1

    1Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI, 2Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI

    *Purpose: Liver transplantation (LT) is an established treatment option for hepatocellular carcinoma (HCC). After 6-month waiting rule was implemented, the impact of wait-listing (WL) time…
  • 2020 American Transplant Congress

    Waiting List Mortality of Liver Tumors

    V. G. Menon, Y. Chen, D. C. Chang, H. Yeh

    Division of Transplantation, Massachusetts General Hospital, Boston, MA

    *Purpose: Liver transplantation has been approved for hepatocellular carcinoma (HCC), hilar cholangiocarcinoma (CCA) and metastatic neuroendocrine tumors (NET), with the aim to produce similar outcomes…
  • 2020 American Transplant Congress

    Hepatocellular Carcinoma Locoregional Therapy: A Comparison of Radiologic Treatment Response and Post-Transplant Pathology

    A. J. Hargrove1, T. Donovan2, K. Fisher3, M. Goodenberger4, A. Langnas1, S. Merani1

    1Department of Surgery, Division of Transplant Surgery, University of Nebraska Medical Center, Omaha, NE, 2Department of Radiology, Division of Interventional Radiology, University of Nebraska Medical Center, Omaha, NE, 3Department of Pathology, University of Nebraska Medical Center, Omaha, NE, 4Department of Radiology, Division of Body Imaging, University of Nebraska Medical Center, Omaha, NE

    *Purpose: Transplantation or resection is the only potentially curative treatment for Hepatocellular Carcinoma (HCC). Locoregional therapy (LRT) is used exclusively in non-transplant candidates or as…
  • 2020 American Transplant Congress

    Effect of 2015 T2 Hepatocellular Carcinoma Exception Policy Implementation on Waitlist Time and Tumor Characteristics

    C. Durkin1, D. E. Kaplan2, T. Bittermann2

    1Internal Medicine, University of Pennsylvania, Philadelphia, PA, 2Gastroenterology, University of Pennsylvania, Philadelphia, PA

    *Purpose: A United Network for Organ Sharing (UNOS) policy change in 2015 created a 6-month delay in the receipt of T2 hepatocellular carcinoma (HCC) exception…
  • 2020 American Transplant Congress

    The Impact of Initial Alpha-Fetoprotein >100 but <1,000 ng/mL and Pre-Transplant alpha-Fetoprotein Reduction on Outcomes after Liver Transplant in Patients with Hepatocellular Carcinoma

    M. L. Goldman1, K. Zhou2, J. L. Dodge1, F. Yao1, N. Mehta1

    1Department of Medicine, UCSF, San Francisco, CA, 2Department of Medicine, USC, Los Angeles, CA

    *Purpose: Under current UNOS policy, hepatocellular carcinoma (HCC) patients with alpha-fetoprotein (AFP) >1,000 ng/mL are required to show a reduction in AFP to 100 but
  • 2020 American Transplant Congress

    Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond UCSF Criteria: Tumor Biology Not the Tumor Number Decide the Long Term Outcome- A Single Center Retrospective Analysis of Using Extended Criteria

    A. Thorat, L. Jeng, S. Hsu, H. Yang, P. Li, T. Chen, K. Poon

    Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan

    *Purpose: HCC is the fifth most common cancer and the third most frequent cause of cancer deaths worldwide. After its introduction for LT in HCC…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 23
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences